发明授权
EP2305194B1 A buprenorphine transdermal patch for use in the treatment of pain for a dosing interval of at least 7 days
无效
透皮贴剂具有为丁丙诺啡在治疗疼痛的用途为7天的给药间隔
- 专利标题： A buprenorphine transdermal patch for use in the treatment of pain for a dosing interval of at least 7 days
- 专利标题（中）： 透皮贴剂具有为丁丙诺啡在治疗疼痛的用途为7天的给药间隔
-
申请号： EP10185240.8申请日： 1998-02-24
-
公开(公告)号： EP2305194B1公开(公告)日： 2012-05-09
- 发明人: Reder, Robert, F. , Goldenheim, Paul, D. , Kaiko, Robert, F.
- 申请人： EURO-CELTIQUE S.A.
- 申请人地址： 2, avenue Charles de Gaulle 1653 Luxembourg LU
- 专利权人： EURO-CELTIQUE S.A.
- 当前专利权人： EURO-CELTIQUE S.A.
- 当前专利权人地址： 2, avenue Charles de Gaulle 1653 Luxembourg LU
- 代理机构： Hansen, Norbert
- 优先权： US38919P 19970224; US939068 19970929
- 主分类号： A61F13/00
- IPC分类号： A61F13/00 ; A61K31/485 ; A61K9/70 ; A61P25/04
摘要：
A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.
公开/授权文献
- EP2305194A1 Sustained analgesia achieved with buprenorphine 公开/授权日：2011-04-06
信息查询
